
Sanofi and Eli Lilly are at two different stages at the moment. In the drug Lantus, Sanofi has the world’s by far bestselling diabetes drug – in fact, with a sales increase of 1.4 billion dollars it was the global pharmaceutical industry’s fastest growing drug in 2012. Eli Lilly, on the other hand, is in the process of returning to the lead group after having fallen behind within diabetes in recent years.
But it is largely between these two companies and Danish Novo Nordisk that the war for control of the global diabetes market will be waged – a market that is estimated to grow to more than 500 billion kroner (USD 86 billion) within the next five years.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app